Results 21 to 30 of about 18,555 (176)
Treatment of dry age-related macular degeneration with dobesilate [PDF]
BMJ Case Reports, 2012 The authors present anatomical and functional evidences of dry age-macular degeneration improvement, after intravitreal treatment with dobesilate. Main outcomes measures were normalisation of retinal structure and function, assessed by optical coherence tomography, fundus-monitored microperimetry, electrophysiology and visual acuity.
P, Cuevas +3 more
openaire +2 more sources
Serum cytokines as biomarkers for dry and wet age related macular degeneration
Delta Journal of Ophthalmology, 2022 Background Age related macular degeneration (AMD) is the most common cause of irreversible visual loss in elderly individuals. Purpose The aim of this study was to identify the potential role of serum pro-inflammatory cytokines, including interleukin-13
Marwa A Fouly +5 more
doaj +1 more source
The Use of Fundus Autofluorescence in Dry Age-Related Macular Degeneration
Türk Oftalmoloji Dergisi, 2021 Fundus autofluorescence (FAF) has been a well-known imaging method for quite some time. However, with developing technologies and novel imaging devices, FAF is being used more often to diagnose and monitor retinal diseases. The density of lipofuscin (LF)
Nedime Şahinoğlu Keşkek +1 more
doaj +1 more source
Overview of clinical trials for dry age-related macular degeneration
Journal of Medical Sciences, 2017 The overall goal of treating age-related macular degeneration (AMD) is to target the underlying cause of the disease and prevent, or at least slow down, the loss of vision, which requires the preservation of the choroid, retinal pigment epithelium (RPE),
Wen-Sheng Cheng +3 more
doaj +1 more source
Dry Age-Related Macular Degeneration
, 2020 Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world in people over 50 years of age (Gehrs et al. 2006). Worldwide, age-related macular degeneration is projected to affect around 196 million people by 2020, increasing to 288 million in 2040 (Wong et al. 2014).
Vikram S. Makhijani +2 more
openaire +1 more source
Targeting the Complement Cascade for Treatment of Dry Age-Related Macular Degeneration
Biomedicines, 2022 Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in the elderly population. AMD is characterized in its late form by neovascularization (wet type) or geographic atrophy of the retinal pigment epithelium cell layer ...
Prem N. Patel +5 more
doaj +1 more source
Dry Age Related Macular Degeneration – Oral Supplements, Which Combination and When ?
Delhi Journal of Ophthalmology, 2018 Age related macular degeneration (AMD), a leading cause of visual loss in the elderly, is emerging as an important public health problem due to the increase in the ageing population. Dry AMD which is the more prevalent form has no effective treatment and
T. Lekha
doaj +1 more source
Journal of Ophthalmology, 2021 Background: The chronic ischemic process caused by impaired hemodynamics in the eye and brain is a component of the pathogenesis of ischemic optic neuropathy and age-related macular degeneration, and requires prompt and adequate treatment. Purpose: To
V. S. Ponomarchuk +2 more
doaj +1 more source
Ophthalmic community perception of new medication needs [PDF]
International Journal of Ophthalmology, 2018 AIM: To survey ophthalmologists (who have participated previously in clinical research) and ophthalmic industry professionals (who have been involved in ocular research and development) to indicate perceived needs for new pharmaceuticals in various ...
William C. Stewart +2 more
doaj +1 more source
Journal of Current OphthalmologyPurpose: To evaluate the impact of cataract surgery on neovascular age-related macular degeneration (nAMD) conversion over a 15-year follow-up period. Methods: This 15-year retrospective study on dry AMD patients compared Group A (cataract surgery) and ...
Komal Agarwal +5 more
doaj +1 more source